Reference ID: 4090621 - Home - Radius
TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as
Download Reference ID: 4090621 - Home - Radius
Information
Domain:
Source:
Link to this page:
Documents from same domain
PROGRAM APPLICATION - radiuspharm.com
radiuspharm.comPROGRAM APPLICATION Prescribers and Patients must review and include the required documentation, as well as complete and sign this form. Fax or mail all pages of the application as well as all required documentation to:
HIGHLIGHTS OF PRESCRIBING INFORMATION …
radiuspharm.comIn this study, the incidence of all-cause mortality was 0.4% in the TYMLOS group and 0.6% in the placebo group. The incidence of serious adverse events was 10% in the TYMLOS group and 11% in the placebo group. The percentage of patients who discontinued study drug due to adverse events was 10% in the TYMLOS group and 6% in the placebo group.
Related documents
Procedures, programs and drugs you must precertify
www.aetna.comProcedures, programs and drugs you must precertify Participating provider precertification list Effective July 1, 2018 . Applies to. 1,2,3,4,9: Aetna
Prior Authorization Program Information - Florida …
www.bcbsfl.com* Important information on page 1 Florida Blue is an Independent Licensee of the Blue Cross and Blue Shield Association Prior Authorization Program Information
Together With Tymlos SAVINGS CARD
www.tymlos.comTogether With Tymlos SAVINGS CARD If your commercial insurance covers TYMLOS, you may be eligible to pay as little as $4 for a 30-day supply* *Eligible commercially insured patients with …
Together With Tymlos (abaloparatide) injection …
www.tymloshcp.comPhone: 1-866-TYMLOS4 | Fax: 1-800-910-4610 For Full Prescribing Information, including Boxed Warning, please see www.TYMLOSPI.com. Information Sharing: I further authorize Radius Health, Inc., and their agents,